Payment overview · 2025
General Payments
$2,362.80
25 reported records · 12 companies
Healthcare provider profile · identity verified
George Prica, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, MO · NPI 1578637567
Verified facts
What the public records show
CMS Open Payments records show George Prica, M.D. received $2,362.80 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $529.41 | 22.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $306.13 | 13.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $300.23 | 12.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $255.16 | 10.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $217.17 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.09 | 8.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $155.15 | 6.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.09 | 5.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $119.35 | 5.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $116.17 | 4.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.53 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.32 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,362.80 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $255.16 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $252.66 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $222.68 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $217.17 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $204.35 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.15 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $127.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.09 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $123.09 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $119.35 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $116.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $101.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $101.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $83.69 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $77.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $70.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 239 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
239 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
239 | 41 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1023 | 283 |
| Losartan Potassium | Losartan Potassium | 696 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 651 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 622 | 169 |
| Omeprazole | Omeprazole | 551 | 155 |
| Metformin Hcl Er | Metformin Hcl | 409 | 126 |
| Quetiapine Fumarate | Quetiapine Fumarate | 367 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 361 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 352 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 75 |
| Gabapentin | Gabapentin | 271 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 86 |
| Mounjaro | Tirzepatide | 239 | 28 |
| Ozempic | Semaglutide | 239 | 41 |
| Lisinopril | Lisinopril | 208 | 62 |
| Allopurinol | Allopurinol | 196 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 193 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 50 |
| Alprazolam | Alprazolam | 172 | 52 |
| Metformin Hcl | Metformin Hcl | 170 | 53 |
| Pioglitazone Hcl | Pioglitazone Hcl | 168 | 52 |
| Atenolol | Atenolol | 164 | 47 |
| Eliquis | Apixaban | 164 | 35 |
| Lamotrigine | Lamotrigine | 164 | 37 |
| Finasteride | Finasteride | 162 | 43 |
| Simvastatin | Simvastatin | 157 | 49 |
| Tramadol Hcl | Tramadol Hcl | 156 | 38 |
| Trazodone Hcl | Trazodone Hcl | 141 | 41 |
| Sertraline Hcl | Sertraline Hcl | 135 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 39 |
| Jardiance | Empagliflozin | 122 | 30 |
| Lorazepam | Lorazepam | 119 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 117 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 43 |
| Xarelto | Rivaroxaban | 114 | 33 |
| Celecoxib | Celecoxib | 108 | 24 |
| Farxiga | Dapagliflozin Propanediol | 108 | 25 |
| Donepezil Hcl | Donepezil Hcl | 103 | 26 |
| Clonazepam | Clonazepam | 102 | 18 |
| Potassium Chloride | Potassium Chloride | 100 | 27 |
| Famotidine | Famotidine | 99 | 33 |
| Furosemide | Furosemide | 97 | 30 |
| Montelukast Sodium | Montelukast Sodium | 96 | 27 |
| Meloxicam | Meloxicam | 92 | 31 |
| Pregabalin | Pregabalin | 90 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 23 |
| Topiramate | Topiramate | 79 | 23 |
| Prednisone | Prednisone | 78 | 41 |
| Lovastatin | Lovastatin | 76 | 16 |
| Spironolactone | Spironolactone | 75 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 17 |
| Carvedilol | Carvedilol | 67 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 24 |
| Estradiol | Estradiol | 60 | 27 |
| Aripiprazole | Aripiprazole | 59 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 41 |
| Lithium Carbonate Er | Lithium Carbonate | 57 | 11 |
| Memantine Hcl | Memantine Hcl | 57 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 57 | 16 |
| Bupropion Xl | Bupropion Hcl | 55 | 17 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 50 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 13 |
| Azithromycin | Azithromycin | 45 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 11 |
| Mupirocin | Mupirocin | 40 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 27 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | suppressed |
| Colchicine | Colchicine | 36 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 11 |
| Diazepam | Diazepam | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 33 |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 12 |
| Cephalexin | Cephalexin | 32 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 12 |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 13 |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Testosterone | Testosterone | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 12 |
| Felodipine Er | Felodipine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,362.80 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GARDASIL 9, Ozempic, QULIPTA, REXULTI, SHINGRIX, Symbravo, TEZSPIRE, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error